1. Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies 
Alex F. Herrera, Arturo Molina 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 7, Pages e4 (July 2018)
DOI: /j.clml
Copyright © 2018 The Authors Terms and Conditions

2. Figure 1 Schematic Diagram of Antibody–Drug Conjugate Structure
Adapted, with permission, from Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC linker chemistry. Pharm Res 2015; 32:
Clinical Lymphoma, Myeloma and Leukemia  , e4DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

3. Figure 2
Mechanism of Antibody–Drug Conjugate (ADC) Drug Delivery. After Binding to the Cognate Antigen, the ADC–Antigen Complex Is Internalized by Receptor-Mediated Endocytosis. Cleavage in the Lysosome Releases the Drug Into the Cytosol. If Not Internalized, Extracellular Drug Release can Occur
Reprinted, with permission, from Nature Publishing Group. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012; 30: ©2012.
Clinical Lymphoma, Myeloma and Leukemia  , e4DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

4. Figure 3
Site-specific Versus Non–Site-Specific Conjugation and Resulting Differences in Product Distribution
Adapted, with permission, from Pankowski S, Bhakta S, Raab H, Polakis P, Junutual JR. Site-specific antibody drug conjugates for cancer therapy. mAbs 2014; 6:34-45.
Clinical Lymphoma, Myeloma and Leukemia  , e4DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions